Winokur 2003.

Methods	Eight‐week double‐blind randomised study
Participants	Patients fulfilling DSM‐IV criteria for major depressive disorder (based on a semi structured clinical interview), a score of at least 18 on the Hamilton Rating Scale for Depression‐21 item (HDRS‐21) and a score of at least 4 on the 3 HDRS‐21 sleep item. Age range: 18‐75 years Exclusion criteria: patients with an history of primary sleep disorder, significant medical problems, current alcohol or substance abuse or dependence, psychosis, or suicidal ideation. Psychotropic drugs were discontinued at least 1 week before study initiation and no subject received any prolonged‐acting central nervous system agent during the previous month.
Interventions	Fluoxetine: 8 participants Mirtazapine: 8 participants Fluoxetine dose range: 20‐40 mg/day Mirazapine dose range: 15‐45 mg/day
Outcomes	Change in the HDRS‐21 score and in Clinical Global Impression (CGI) score
Notes	Funding: by industry
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further information
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Double blind, double dummy, no further information
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double blind, double dummy, no further information
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Double blind, double dummy, no further information
Incomplete outcome data (attrition bias) All outcomes	High risk	Number and reasons for dropout not clearly reported Only HDRS baseline scores reported
Selective reporting (reporting bias)	High risk	Side effects not reported. Number of responders not reported
Other bias	High risk	Quote: "funds for this study were provided through on unrestricted educational grant from Organon, Inc" and this industry produces venlafaxine